<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04900818</url>
  </required_header>
  <id_info>
    <org_study_id>TJ033721STM101</org_study_id>
    <nct_id>NCT04900818</nct_id>
  </id_info>
  <brief_title>Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Mab Biopharma Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Mab Biopharma Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety,&#xD;
      tolerability, MTD PK, and PD of TJ033721 in subjects with advanced or metastatic solid&#xD;
      tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLTs)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of AEs</measure>
    <time_frame>Up to 100 days post last dose</time_frame>
    <description>The CTCAE criteria will be used to assess adverse events on this trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated or administered dose (MTD, MAD)</measure>
    <time_frame>28 Days</time_frame>
    <description>Based on DLT definitions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameters: AUC∞</measure>
    <time_frame>Up to 100 days post last dose</time_frame>
    <description>Area under the curve from time zero extrapolated to infinity (AUC∞)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameters: AUCt</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>AUC from time zero to the time of the last quantifiable concentration (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameters: Cmax</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Tmax</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Time of peak concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: T1/2</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Investigational Product (IP) half-life (T1/2)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Advanced Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Carcinoma</condition>
  <condition>Esophageal Adenocarcinoma</condition>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation: TJ033721</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation:: TJ033721 will be administered at up to 8 dose levels (0.1, 0.3, 1, 3, 5, 8, 12 and 15 mg/kg) bi-weekly (Q2W)&#xD;
During dose expansion, TJ033721 will be administered Q2W, starting at the highest dose to have cleared the DLT period.&#xD;
After the conclusion of dose expansion TJ033721 will be administered Q2W at the MAD or RP2D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ033721</intervention_name>
    <description>Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb)</description>
    <arm_group_label>Dose Escalation: TJ033721</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with advanced or metastatic solid tumor in subjects whose disease has&#xD;
             progressed despite standard therapy, or who has no further standard therapy, or who is&#xD;
             unsuitable for available standard treatment options.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 with adequate&#xD;
             organ function&#xD;
&#xD;
        For dose expansion study only:&#xD;
&#xD;
          -  Advanced or metastatic gastric cancer, gastroesophageal junction carcinoma, esophageal&#xD;
             adenocarcinoma, and pancreatic ductal adenocarcinoma without further standard therapy&#xD;
             or unsuitable for available standard treatment options.&#xD;
&#xD;
          -  Must have CLDN18.2-positive tumor expression as determined by the CLDN18.2 IHC assay&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Prior exposure to CLDN18.2 -targeted therapy&#xD;
&#xD;
          -  Prior exposure to 4-1BB agonists&#xD;
&#xD;
          -  Known active or chronic Hepatitis B or Hepatitis C, other hepatitides&#xD;
&#xD;
          -  Unstable/active ulcer or digestive tract bleeding within 6 weeks&#xD;
&#xD;
          -  Active autoimmune disease requiring systemic treatment within the past 2 years&#xD;
&#xD;
          -  Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or&#xD;
             pneumonitis requiring treatment&#xD;
&#xD;
          -  Known active CNS metastases and/or carcinomatous meningitis. Subjects with previously&#xD;
             treated brain metastases may participate provided they are clinically stable and&#xD;
             without requirement of steroid treatment for at least 14 days prior to first dose of&#xD;
             study treatment;&#xD;
&#xD;
          -  New York Heart Association (NYHA) Class 3 or 4 congestive heart failure,&#xD;
             severe/unstable angina, myocardial infarction (MI), symptomatic congestive heart&#xD;
             failure, cerebrovascular accident, transient ischemic attack (TIA), arterial embolism,&#xD;
             pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), deep vein&#xD;
             thrombosis, or coronary artery bypass grafting (CABG) in the previous 6 months&#xD;
&#xD;
          -  Diagnosis of immunodeficiency such as known active HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>US Site Head</last_name>
    <phone>301-294-4408</phone>
    <email>us.info@i-mabbiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stern Center for Cancer Clinical Trials and Research</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCHealth Cancer Care - Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Research, LLC.</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mass General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UW Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

